HC Wainwright & Co. Maintains Buy on Stoke Therapeutics, Raises Price Target to $50

Benzinga · 3d ago
HC Wainwright & Co. analyst Ananda Ghosh maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $35 to $50.